Table 2.
Summary of pooled seropositivity rates for patients with hematologic malignancies by underlying disease type and number of vaccine doses
| No. of patients | Single-arm studies | Malignancy arm of comparator studies | Control arm of comparator studies | Intervention vs control cohort | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pooled response rate (95% CI) | I2 (%) | P | Pooled response rate (95% CI) | I2 (%) | P | Pooled response rate (95% CI) | I2 (%) | P | OR (95% CI) | P | I2 (%) | P | ||
| Overall: Patients with hematologic malignancies | ||||||||||||||
| After second dose | 4733 | 0.62 (0.55-0.70) | 92 | <.01 | 0.66 (0.57-0.75) | 93 | <.01 | 0.99 (0.97-1.00) | 53 | 0.01 | 0.04 (0.02-0.08) | <.01 | 70 | <.01 |
| After first dose | 2331 | 0.51 (0.38-0.64) | 92 | <.01 | 0.37 (0.23-0.51) | 90 | <.01 | 0.78 (0.62-0.95) | 98 | <.01 | 0.10 (0.04-0.29) | <.01 | 86 | <.01 |
| Myeloma | ||||||||||||||
| After second dose | 1218 | 0.80 (0.64-0.95) | 85 | <.01 | 0.76 (0.70-0.82) | 90 | <.01 | 0.98 (0.95-1.00) | 71 | <.01 | 0.09 (0.03-0.29) | <.01 | 49 | .08 |
| After first dose | 685 | 0.43 (0.18-0.68) | 91 | <.01 | 0.29 (0.09-0.48) | 81 | <.01 | 0.64 (0.42-0.87) | 76 | <.01 | 0.23 (0.05-0.99) | .05 | 49 | .11 |
| CLL | ||||||||||||||
| After second dose | 1446 | 0.51 (0.37-0.65) | 91 | <.01 | 0.51 (0.34-0.68) | 56 | .06 | 1.00 (0.99-1.00) | 0 | .07 | 0.01 (0.01-0.03) | <.01 | 0 | .9 |
| After first dose | 111 | Single study | 0.18 (0.00-1.00) | 89 | <.01 | 0.92 (0.52-1.00) | 0 | .32 | 0.03 (0.00-0.80) | .05 | 0 | .60 | ||
| Lymphoma | ||||||||||||||
| After second dose | 1227 | 0.52 (0.28-0.75) | 97 | <.01 | 0.55 (0.35-0.76) | 84 | <.01 | 0.99 (0.98-1.00) | 0 | .72 | 0.02 (0.01-0.02) | <.01 | 0 | 1.0 |
| After first dose | 69 | No studies available | 0.33 (0.00-1.00) | 93 | <.01 | 0.95 (0.09-1.00) | 71 | .06 | 0.01 (0.0-1.24) | .05 | 0 | .7 | ||
| HSCT and cellular therapies | ||||||||||||||
| After second dose | 401 | 0.61 (0.42-0.80) | 88 | .05 | Single study | Single study | Single study | |||||||
| After first dose | 21 | Single study | No studies available | No studies available | No studies available | |||||||||
| Acute leukemia and MDS | ||||||||||||||
| After second dose | 113 | 0.93 (0.80-1.00) | 29 | .24 | Single study | Single study | Single study | |||||||
| After first dose | 13 | Single study | Single study | Single study | Single study | |||||||||
| MPN and CML | ||||||||||||||
| After second dose | 281 | 0.88 (0.72-1.00) | 70 | .01 | 0.87 (0.81-0.92) | 0 | .83 | 0.99 (0.98-1.00) | 0 | .90 | 0.07 (0.0-1.55) | .06 | 0 | .77 |
| After first dose | 222 | 0.71 (0.30-1.00) | 76 | .01 | 0.54 (0.37-0.71) | 0 | .46 | 0.85 (0.51-1.00) | 90 | <.01 | 0.13 (0.01-1.71) | .09 | 88 | <.01 |
AEs, adverse events; CLL, chronic lymphotic leukemia; CML, chronic myeloid leukemia; HSCT, hematopoietic stem cell transplantation; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasms.